Abstract

Acute myocardial infarction (AMI) with subsequent ventricular dysfunction is the most frequent cause of cardiogenic shock (CS) accounting for about 80% of cases (1). CS remains the leading cause of death in AMI with mortality rates still approaching 40–50% (2,3). The treatment of AMI-induced CS principally consists of early revascularization and intensive care treatment with inotropes, vasopressors, sedation and mechanical ventilation. The most severe cases of CS can be treated with mechanical circulatory support, as a bridge to recovery of cardiac function, or sometimes as a bridge to heart transplantation.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.